BMS-754807

For research use only. Not for use in humans.

目录号:S1124

BMS-754807 Chemical Structure

Molecular Weight(MW): 461.49

BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂,在无细胞试验中IC50为1.8 nM/1.7 nM,对Met,Aurora A/B,TrkA/B和Ron作用稍弱,对Flt3, Lck,MK2,PKA,PKC等几乎没有抑制活性。Phase 2。

规格 价格 库存 购买数量  
RMB 1480.09 现货
RMB 2214.12 现货
RMB 6299.66 现货
RMB 16953.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的BMS-754807发表文献23篇:

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂,在无细胞试验中IC50为1.8 nM/1.7 nM,对Met,Aurora A/B,TrkA/B和Ron作用稍弱,对Flt3, Lck,MK2,PKA,PKC等几乎没有抑制活性。Phase 2。
特性 胰岛素样生长因子-1R/IR家族激酶的多重抑制剂
靶点
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
1.7 nM 1.8 nM 4.1 nM 5.6 nM 7.4 nM
体外研究

BMS-754807 有效抑制人类多种不同组织来源的肿瘤细胞系的生长,包括间充质(尤文氏肉瘤,横纹肌肉瘤,神经母细胞瘤,和脂肪肉瘤),上皮(乳腺,肺,胰腺,结肠,和胃),和造血(多发性骨髓瘤和白血病)组织,IC50值从5 nM 到 365 nM。BMS-754807 抑制 IGF-1R-Sal 细胞和 RH41细胞增殖,IC50分别为7 nM 和5 nM。BMS-754807作用于IGF-1R-Sal, Rh41 和 Geo细胞,抑制IGF-1R磷酸化,IC50分别为13 nM, 6 nM 和 21 nM。BMS-754807作用于 IGF-1R-Sal, Rh41 和Geo细胞,抑制Akt磷酸化,IC50 分别为22 nM, 13 nM 和 16 nM。BMS-754807诱导Rh41细胞凋亡。[1] BMS-754807作用于IGF-Sal 细胞系,抑制IGF-1R (IC50 = 13nM) 和下游靶点Akt (IC50 = 22nM) 和MAPK(IC50 = 13nM) 的磷酸化。[2] 在儿科临床前期试验计划(PPTP)中,BMS-754807作用于23种细胞系,平均EC50值为0.62 µM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGF-Sal MmLNT4lv[XOnIHHzd4F6 Mmr1bY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCLR1[tNXIhMEmFNUCgQUAyO26PKTDhcoQhfGinIHTve45{fHKnYX2geIFz\2W2czDBb5QhMEmFNUCgQUAzOm6PKTDhcoQhVUGSSzCoTWM2OCB;IEGzcm0q NFW5OpUyQTd5OECyOC=>
IGF-Sal MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXPGbFF{UUN3ME23JI5O NW\WPYVsOTl5N{iwNlQ>
CCRF-CEM (ALL) NIrnS2FIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVzDdm1vhjVizszN NGDhWGtFVVOR Mme5TWM2OD1zLkKzPUDPxE1? MXyxPVk6PjJ5Mh?=
PC3 NF\sNpNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGizcYZ,PSEQvF2= M4rJbWROW09? NXHae25KUUN3ME2wMlk3PSEQvF2= NWjLTYcxOTl7OU[yO|I>
JD M3\wW2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mn\RglUh|ryP NF7CNHdFVVOR M3PVW2lEPTB;MD6zPVEh|ryP MUWxPVk6PjJ5Mh?=
DU145 NW\pN3RtT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NF73V2R,PSEQvF2= MlPaSG1UVw>? NHjyeIVKSzVyPUGuOFY2KM7:TR?= NYrpTFdTOTl7OU[yO|I>
KAG NIjPZnRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4PoXJ42KM7:TR?= NGO4T4ZFVVOR MlfTTWM2OD1zLk[2OUDPxE1? NVK1O2lQOTl7OU[yO|I>
K-562 (CML) MkDRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmHjglUh|ryP Ml;ISG1UVw>? NVG1VmJ6UUN3ME2yMlMxOiEQvF2= NUfoZ2FJOTl7OU[yO|I>
B6-P210 (Murine ALL) NHLDc4RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Ml7sglUh|ryP MVXEUXNQ NInFOIpKSzVyPUGuNlk{KM7:TR?= NX6yUXJuOTl7OU[yO|I>
LN CAP-FGC M1j4UGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3zTTZ42KM7:TR?= NUH3fWczTE2VTx?= MVzJR|UxRTFwNEO0JO69VQ>? NFqwUJEyQTl7NkK3Ni=>
VW M3HtbWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{TETp42KM7:TR?= NIDHbVRFVVOR MXnJR|UxRTBwMEG5JO69VQ>? MV2xPVk6PjJ5Mh?=
MV411 (B Myelomonocytic) NEj3UXBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4PnVJ42KM7:TR?= NWD1cYNMTE2VTx?= MX3JR|UxRTBwM{Og{txO NHLtZ28yQTl7NkK3Ni=>
MDA-PCa-2b MkLJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnjqglUh|ryP M2O3dWROW09? M3nzdWlEPTB;MD6wPVgh|ryP M2PUWlE6QTl4Mkey
LG NVLWSpg6T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWH+OUDPxE1? NUDsdIhCTE2VTx?= NUjkbolmUUN3ME2wMlA{QCEQvF2= MmDINVk6QTZ{N{K=
RS411 (B cell precursor-ALL) MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{f4cp42KM7:TR?= MljPSG1UVw>? MVHJR|UxRTBwMUCyJO69VQ>? MXexPVk6PjJ5Mh?=
22-r-1 NFjhbphIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Ml3OglUh|ryP MWfEUXNQ NGewR3NKSzVyPUCuNVc2KM7:TR?= NID2U5oyQTl7NkK3Ni=>
5838 MmqxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MV\+OUDPxE1? NXTWRXl{TE2VTx?= MUDJR|UxRTBwMEO0JO69VQ>? NHf2dI0yQTl7NkK3Ni=>
P388 (Murine) NYrifItXT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmX2glUh|ryP MX;EUXNQ Moj0TWM2OD12LkK3JO69VQ>? M3v4SFE6QTl4Mkey
A2780/S NHHC[5RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkHtglUh|ryP NYPPenBFTE2VTx?= NInYNWRKSzVyPUCuNVIzKM7:TR?= NVPRUZBnOTl7OU[yO|I>
RDES MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIHFTmF,PSEQvF2= M4\VSmROW09? NImzZ4RKSzVyPUCuNFEzKM7:TR?= MX2xPVk6PjJ5Mh?=
B6-T315I (Murine B-ALL) M3v0VGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVP6OoZwhjVizszN MXnEUXNQ NV\iWGlNUUN3ME2yMlg{KM7:TR?= M4LQbFE6QTl4Mkey
TOV 112D MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlT2glUh|ryP NYTE[Zl2TE2VTx?= NUDpem1xUUN3ME2yMlE1PiEQvF2= Mmi3NVk6QTZ{N{K=
TC32 Mn[3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MkmyglUh|ryP MX\EUXNQ MY\JR|UxRTBwMEC4JO69VQ>? MmnQNVk6QTZ{N{K=
HL60 (acute myelocytic) NU\i[FJ1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NIL1W29,PSEQvF2= M3XRWmROW09? NEHaSVRKSzVyPUCuNVIh|ryP NG[zcYUyQTl7NkK3Ni=>
TOV 21G NIXvbHVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3\JVJ42KM7:TR?= NHTzOGJFVVOR NEjufGRKSzVyPUSuNlc6KM7:TR?= Mn:4NVk6QTZ{N{K=
TC71 MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NW\jWJNQhjVizszN M4Tne2ROW09? NGPodG9KSzVyPUCuNFE1KM7:TR?= MlezNVk6QTZ{N{K=
HPN-ALL (T-cell) Mki1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGDjV|R,PSEQvF2= NFT5PHpFVVOR MUnJR|UxRTBwNUKg{txO M4fQOFE6QTl4Mkey
A2780R NXPncpo3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWnOfI5zhjVizszN M3vyZWROW09? NV[1N3RlUUN3ME2xMlU3PCEQvF2= MYGxPVk6PjJ5Mh?=
Rh1 MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Moj4glUh|ryP Mn3ZSG1UVw>? NWqyS|VDUUN3ME2wMlAzPyEQvF2= M{LWW|E6QTl4Mkey
Kasumi-1 (acute myeloid) NH;kOIpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmjjglUh|ryP MlO1SG1UVw>? M1fkO2lEPTB;MD6xOkDPxE1? MojlNVk6QTZ{N{K=
sk-ov-3 M1jQO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWfXc3RthjVizszN MkG0SG1UVw>? Mk\KTWM2OD13LkGg{txO Mn3mNVk6QTZ{N{K=
ME MnXoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3:5Tp42KM7:TR?= NWTpdJB7TE2VTx?= MW\JR|UxRTBwMEG1JO69VQ>? MX[xPVk6PjJ5Mh?=
L1210 (Murine lymphocytic) NYHvVnFPT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYnTVmU6hjVizszN MkjNSG1UVw>? NIO1Sm9KSzVyPUKuN|kh|ryP NXvLRZFPOTl7OU[yO|I>
sw-626 MmftS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUfKNmozhjVizszN NXrqOGh7TE2VTx?= MVLJR|UxRTJwM{C2JO69VQ>? NIjSXo0yQTl7NkK3Ni=>
CTR MofxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4m2b542KM7:TR?= NVLtVFF5TE2VTx?= NF75ZnFKSzVyPUCuNlU{KM7:TR?= NHLt[HQyQTl7NkK3Ni=>
ML2 (Myelomonocytic) MlXOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYDnZY5ThjVizszN MVjEUXNQ NIHtc45KSzVyPUCuNFkh|ryP M{\R[|E6QTl4Mkey
ovcar-3 NHnSfI1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFrwTFl,PSEQvF2= M1LGXWROW09? M3ro[2lEPTB;NTFOwG0> MmnINVk6QTZ{N{K=
Rh36 M{SyTWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHfUblZ,PSEQvF2= MX7EUXNQ MlTnTWM2OD1zLkSzNkDPxE1? NUXWPG9ZOTl7OU[yO|I>
MOLM-13 (acute myeloid) M3\icWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYL+OUDPxE1? NHHWeYxFVVOR Mnf5TWM2OD1yLkSyJO69VQ>? M3\JUVE6QTl4Mkey
ovcar-4 MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXXSNm5VhjVizszN NH3QU5RFVVOR MWfJR|UxRTFizszN NX;VZlBiOTl7OU[yO|I>
Rh41 NXnaTZNnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1L3cp42KM7:TR?= MYPEUXNQ MVLJR|UxRTBwMEC1JO69VQ>? NXX6b|k5OTl7OU[yO|I>
Mutz 2 (acute myeloid) NX6zOIoyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHfDN3N,PSEQvF2= NEjxXGtFVVOR Ml3zTWM2OD1zLkG1JO69VQ>? Mlj6NVk6QTZ{N{K=
ovcar-5 M3S2bWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFjYcmt,PSEQvF2= M13EUGROW09? Ml\sTWM2OD1yLkC1JO69VQ>? M{\ncVE6QTl4Mkey
RD1 NFTBOo5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYXrS2Z3hjVizszN NVTiTG15TE2VTx?= M13SOmlEPTB;MD6wOlgh|ryP NE\SWVUyQTl7NkK3Ni=>
OCI-AML 2 (acute myeloid) M3nmfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUn+OUDPxE1? NFHCU5VFVVOR MULJR|UxRTNwM{Og{txO NID0bpUyQTl7NkK3Ni=>
786-O MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MU\+OUDPxE1? M3u3UGROW09? MlvaTWM2OD1zLk[0O{DPxE1? Mmr4NVk6QTZ{N{K=
A673 NWjkUVJOT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHr5UYp,PSEQvF2= M3zYbmROW09? MVfJR|UxRTBwNEC4JO69VQ>? NYjTO|VNOTl7OU[yO|I>
TALL-1 (T-cell) MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mlf3glUh|ryP MV;EUXNQ M2m0PGlEPTB;MT6yPEDPxE1? NF3aO4QyQTl7NkK3Ni=>
151-B NULkXIhWT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYTNfYlGhjVizszN MYrEUXNQ NF\YeG5KSzVyPUKuOlch|ryP M2TyXlE6QTl4Mkey
PFSK-1 NEjFPItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUn+OUDPxE1? NWS3N4h3TE2VTx?= NXO0OZA5UUN3ME2wMlE{OiEQvF2= NVroUm8zOTl7OU[yO|I>
THP-1 NYDVfYhoT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3;yOp42KM7:TR?= Mn32SG1UVw>? NYroS4M1UUN3ME22MlU5KM7:TR?= MYOxPVk6PjJ5Mh?=
HEK293 MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3PNfZ42KM7:TR?= MWXEUXNQ MlnoTWM2OD1yLkmxOUDPxE1? NXvycYFQOTl7OU[yO|I>
DAOY M3zHbGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NIC3R|l,PSEQvF2= MV7EUXNQ NGXV[ZBKSzVyPUGuPVc6KM7:TR?= MX2xPVk6PjJ5Mh?=
SET2 NFT3d|RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHzDV2J,PSEQvF2= NG\TTmpFVVOR M4XP[WlEPTB;MD6yPVgh|ryP MY[xPVk6PjJ5Mh?=
HTB-46 MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mn;HglUh|ryP NXfHNYJYTE2VTx?= M3voeGlEPTB;NT6yOUDPxE1? MW[xPVk6PjJ5Mh?=
SK-NAS NXTFbmpST3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3vPOZ42KM7:TR?= MnPPSG1UVw>? NVTO[3hWUUN3ME2wMlQ6PyEQvF2= NEPlPIEyQTl7NkK3Ni=>
CTLL2 NVrZTWJvT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGHETIl,PSEQvF2= MXXEUXNQ MmCwTWM2OD5zLkCwJO69VQ>? MWWxPVk6PjJ5Mh?=
HTB-47 M13wfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1G0bp42KM7:TR?= NHHlTZBFVVOR M3qzUGlEPTB;Mj6wOVYh|ryP NEPzTpUyQTl7NkK3Ni=>
LAN-1 MlnqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NELBWmx,PSEQvF2= MmHSSG1UVw>? NUXZW2NLUUN3ME2wMlA1KM7:TR?= Mn3vNVk6QTZ{N{K=
ST486 NVqxTpFqT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXP+OUDPxE1? NVTxcHNYTE2VTx?= NVzpV3dQUUN3ME2xMlE6KM7:TR?= NYHtZZRROTl7OU[yO|I>
HS766T MoH3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmX6glUh|ryP NV\ZSW1yTE2VTx?= MXXJR|UxRTJwMECxJO69VQ>? NGDhSIEyQTl7NkK3Ni=>
IMR-32 NIHn[4FIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHfGdZZ,PSEQvF2= MlrUSG1UVw>? NFLZS2xKSzVyPUCuNlYyKM7:TR?= MYGxPVk6PjJ5Mh?=
Daudi (Burkitt's) NGDmWWZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mki0glUh|ryP NUDIb|Z4TE2VTx?= NVnZbFJxUUN3ME2yMlY{PyEQvF2= MWqxPVk6PjJ5Mh?=
Aspc-1 MmfFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Ml35glUh|ryP Mkn2SG1UVw>? MVHJR|UxRTBwM{e5JO69VQ>? NXTsd4g5OTl7OU[yO|I>
SK-NSH MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEXvdHB,PSEQvF2= MlPTSG1UVw>? M2TIN2lEPTB;MD6xN|kh|ryP MX[xPVk6PjJ5Mh?=
MEC-1 (Chronic B cell) MnPDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NF;1VnJ,PSEQvF2= MoXKSG1UVw>? NGLxRo9KSzVyPUKuOlM4KM7:TR?= M4\nRlE6QTl4Mkey
Capan-2 NWXwd2N1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoLGglUh|ryP NX22endTTE2VTx?= M4jY[GlEPTB;MT63O|Qh|ryP MkfyNVk6QTZ{N{K=
SHSY5Y NHfL[|FIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIfhTXB,PSEQvF2= M4XkTGROW09? NXHBb4xyUUN3ME2wMlExPiEQvF2= NW\aXY1vOTl7OU[yO|I>
U937 (Histioocytic) Mnz5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYjuPJJmhjVizszN NUj6U5VvTE2VTx?= MmnxTWM2OD53LkCwJO69VQ>? MVexPVk6PjJ5Mh?=
Bxpc-1 NXzNe2JoT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Ml;iglUh|ryP M1W0PGROW09? NFziNYZKSzVyPUGuPVI1KM7:TR?= NILjTlMyQTl7NkK3Ni=>
Bxpc-3 NY\ndFlFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYX+OUDPxE1? M4PM[WROW09? NV\5XJk1UUN3ME61MlAxKM7:TR?= MnezNVk6QTZ{N{K=
HTB-92 NU\EVYcyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NW\NS2pWhjVizszN NE\Vd2hFVVOR NYfOdoxOUUN3ME2xMlAzKM7:TR?= NVrzOGFWOTl7OU[yO|I>
OCI-LY10 (B-cell) MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1PFUp42KM7:TR?= NXHTOJhHTE2VTx?= M4XjOGlEPTB;MD60OUDPxE1? M{LtfFE6QTl4Mkey
PANC-1 M{PqcGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmTGglUh|ryP MlexSG1UVw>? MXTJR|UxRjVwMECg{txO NWrScHdWOTl7OU[yO|I>
To184.T M{fDUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MknBglUh|ryP NVXoenBqTE2VTx?= MmD1TWM2OD1yLkS2PUDPxE1? M2PHUVE6QTl4Mkey
OCI-LY19 (B-cell) MnLaS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUf+OUDPxE1? MkGxSG1UVw>? Mke0TWM2OD1yLkSg{txO MojZNVk6QTZ{N{K=
PANC-1 BM M363d2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXr+OUDPxE1? MXHEUXNQ Mk\WTWM2OD53LkCwJO69VQ>? NUTQbGhkOTl7OU[yO|I>
SA-4 NY\XOnI2T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{[4bp42KM7:TR?= Ml;5SG1UVw>? M2LpdWlEPTB;MT6zNFEh|ryP M4L3bVE6QTl4Mkey
RPMI 8226 NXrJT21rT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2POWZ42KM7:TR?= MnzBSG1UVw>? MWXJR|UxRTFwMkmzJO69VQ>? NFHqVWUyQTl7NkK3Ni=>
HPAF-II NWX1NpMzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGm0d3V,PSEQvF2= NEfZSZlFVVOR Mo\NTWM2OD1yLk[0OEDPxE1? NU\EZ3NmOTl7OU[yO|I>
SHP-77 MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mk\hglUh|ryP MX\EUXNQ MoDqTWM2OD1zLki4PEDPxE1? MYWxPVk6PjJ5Mh?=
U266 B1 MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MX;+OUDPxE1? NV7yOpFWTE2VTx?= NVLKdHh1UUN3ME2xMlY3QSEQvF2= NG\2bHMyQTl7NkK3Ni=>
Hs700t NXywbHpwT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUf+OUDPxE1? MkXOSG1UVw>? MkDwTWM2OD1yLkKzNUDPxE1? NVvofXBZOTl7OU[yO|I>
NCI-446 MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFzsUXR,PSEQvF2= M1ixcmROW09? NU\jXXlSUUN3ME2xMlE2PCEQvF2= NVO0OZdHOTl7OU[yO|I>
H929 NFTBOYpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVL+OUDPxE1? NIfOOYVFVVOR M1H2T2lEPTB;MD6wNVQh|ryP MoWxNVk6QTZ{N{K=
PL45 Mlf6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWL0V|hnhjVizszN M4TQdmROW09? MoTVTWM2OD1{LkK1OUDPxE1? NV:zW3RrOTl7OU[yO|I>
NCI-H383 NILWVWhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2PLNp42KM7:TR?= NV\yZVdtTE2VTx?= M{n2PWlEPTB-NT6wNEDPxE1? MYCxPVk6PjJ5Mh?=
JJN3 NVLZWXhXT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3L1UZ42KM7:TR?= MnrYSG1UVw>? NEPhdY9KSzVyPUKuOFM{KM7:TR?= MoTkNVk6QTZ{N{K=
SU.86.86 NH;NeVhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4[5Op42KM7:TR?= M{X6[GROW09? NETpUHJKSzVyPUKuOlczKM7:TR?= NH7KUW4yQTl7NkK3Ni=>
H1299 M{fiXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mn7SglUh|ryP NX3yRndsTE2VTx?= MWLJR|UxRjVwMECg{txO NHTTUWYyQTl7NkK3Ni=>
MDA-MB-468 Mn\ES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NV7ZboV1hjVizszN MmnBSG1UVw>? M2O0bGlEPTB;MD61NFQh|ryP NGXNb|kyQTl7NkK3Ni=>
SW1990 M2eyWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2LhNp42KM7:TR?= MVrEUXNQ Ml7aTWM2OD1yLkiyOkDPxE1? NEfJdYcyQTl7NkK3Ni=>
Calu-6 NIPkO|VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX7+OUDPxE1? Mk[3SG1UVw>? MnP0TWM2OD53LkCwJO69VQ>? NIewdnAyQTl7NkK3Ni=>
MDA-MB-231 M4jFeWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWP+OUDPxE1? NGnjfFNFVVOR MXjJR|UxRTFwNkS4JO69VQ>? MnjmNVk6QTZ{N{K=
SW-684 NWTBZWxYT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4HDeJ42KM7:TR?= NVf5dnBETE2VTx?= M2HQbGlEPTB-NT6wNEDPxE1? MUOxPVk6PjJ5Mh?=
H209 NXrGSnpGT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoDJglUh|ryP NFTnb|lFVVOR M3G1RmlEPTB;MT6xPVMh|ryP M4jKWlE6QTl4Mkey
MDA-MB-231T M1XSTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYWzcVdnhjVizszN MojjSG1UVw>? NH;qSWxKSzVyPkWuNFAh|ryP NEXLR20yQTl7NkK3Ni=>
HT1080/S M3PqfWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NEnBfId,PSEQvF2= NHLib3BFVVOR NFnUU21KSzVyPUCuOVMyKM7:TR?= M2\obVE6QTl4Mkey
H526 0.044 NUXsSXZET3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Moj1glUh|ryP NIOybodFVVOR NGj4UXlKSzVyPUCuNFQ1KM7:TR?= NU[5W4JiOTl7OU[yO|I>
DU4475 2.431 NWX1TIpIT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MonsglUh|ryP MX\EUXNQ MorKTWM2OD1{LkSzNUDPxE1? NFH2UZQyQTl7NkK3Ni=>
HCT116 Mln5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoPZglUh|ryP NFSxcW1FVVOR NGrZXYNKSzVyPUCuPFUzKM7:TR?= MVyxPVk6PjJ5Mh?=
M109 MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXL+OUDPxE1? NYPrWoZCTE2VTx?= MoLTTWM2OD1zLkC1OUDPxE1? NFm1OY0yQTl7NkK3Ni=>
BT549 MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Ml32glUh|ryP NXXNT3pzTE2VTx?= M{K5NGlEPTB;MT62OFUh|ryP NVf4RWRIOTl7OU[yO|I>
HCT116/VM46 MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVzIUJFrhjVizszN MYnEUXNQ Mn;LTWM2OD1zLkewNkDPxE1? M{flWlE6QTl4Mkey
H460 MmXLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3;sOJ42KM7:TR?= NGLDNHBFVVOR MXTJR|UxRTBwN{m1JO69VQ>? MYqxPVk6PjJ5Mh?=
MCF-7 Ml;tS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1fEO542KM7:TR?= MWnEUXNQ MULJR|UxRTBwMEG2JO69VQ>? NHrBZ2MyQTl7NkK3Ni=>
GEO MnGwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWD1OnhkhjVizszN MYnEUXNQ Moe0TWM2OD1yLkO1OkDPxE1? MUWxPVk6PjJ5Mh?=
H441 0.646 MmWzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnHuglUh|ryP M4fUcWROW09? M2\jUGlEPTB;MD62OFYh|ryP NXfMWZpEOTl7OU[yO|I>
MCF-7-807R NFS1WYJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4Pnfp42KM7:TR?= M1q1eWROW09? MX;JR|UxRTBwNEmg{txO Mmm5NVk6QTZ{N{K=
Colo205 MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmTxglUh|ryP MVPEUXNQ M4HnT2lEPTB;MD6xNFQh|ryP NH3JTGYyQTl7NkK3Ni=>
H292 NVj1ZZB1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVX+OUDPxE1? Mn:4SG1UVw>? NEfkdJFKSzVyPUCuO|g5KM7:TR?= NVPJbpV[OTl7OU[yO|I>
BT474 (S) Ml;nS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1[3bp42KM7:TR?= NWHGd2Z3TE2VTx?= NVPWSIk4UUN3ME2yMlQxOyEQvF2= NFLJU2MyQTl7NkK3Ni=>
HT-29 NYLUdFlVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYezdlZRhjVizszN M{LscmROW09? NFi5UmVKSzVyPUKuNVA{KM7:TR?= NFX1dYMyQTl7NkK3Ni=>
A549 NVG3ZnRGT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGjYW5F,PSEQvF2= M4HxdWROW09? MUDJR|UxRTBwNke1JO69VQ>? Mnv5NVk6QTZ{N{K=
BT474-M1 NUjtbYszT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlntglUh|ryP MnzKSG1UVw>? NVfNVGVGUUN3ME2yMlM3PSEQvF2= MYOxPVk6PjJ5Mh?=
SW480 NG\od|hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYm0PXNJhjVizszN MX3EUXNQ M1W5OmlEPTB-NT6wNEDPxE1? NHLER2wyQTl7NkK3Ni=>
L2987 M1Hobmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NX6zcIVEhjVizszN NXPEdZV[TE2VTx?= M1vlb2lEPTB;MD60OFIh|ryP M2H4[|E6QTl4Mkey
AU565 M1v0W2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mlu0glUh|ryP NWrye2p4TE2VTx?= MULJR|UxRTRwOUeg{txO NYTpUlJEOTl7OU[yO|I>
SW403 NWTx[4NqT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFHsbGR,PSEQvF2= MmW3SG1UVw>? NHW1WIJKSzVyPUCuNlIh|ryP NUH3e|BROTl7OU[yO|I>
H1437 MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUTJR|E3hjVizszN MULEUXNQ M3[2[GlEPTB;MD61NlMh|ryP MlrmNVk6QTZ{N{K=
BT-20 MmS0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoXZglUh|ryP NH\MS5FFVVOR NUL1XG9lUUN3ME2zMlU3OiEQvF2= M{fuPFE6QTl4Mkey
Colo320HSR MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXz+OUDPxE1? M1HuOWROW09? Mo\jTWM2OD1yLkCxNUDPxE1? MmP6NVk6QTZ{N{K=
H2087 NF60[2xIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkTKglUh|ryP MUDEUXNQ M3H4VmlEPTB-MT6wNEDPxE1? MUKxPVk6PjJ5Mh?=
HCC1419 M{PYXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmD5glUh|ryP MX\EUXNQ Mlz0TWM2OD1{LkWxO{DPxE1? MYSxPVk6PjJ5Mh?=
WiDr NF33UXVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoDXglUh|ryP M1zDPWROW09? NUnS[VIyUUN3ME2wMlA4PiEQvF2= NVLXR|k6OTl7OU[yO|I>
H661 0.573 NYX5bmZYT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVL6O|M1hjVizszN MmXrSG1UVw>? MnW3TWM2OD1yLkW3N{DPxE1? NF;WcoMyQTl7NkK3Ni=>
HCC-38 NFnkNYdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoPXglUh|ryP NFvEU|lFVVOR NIPCVHZKSzVyPkWuNFAh|ryP MUixPVk6PjJ5Mh?=
LS174T MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NG\CbFJ,PSEQvF2= MYLEUXNQ MWrJR|UxRTBwNUO1JO69VQ>? NEnPRYYyQTl7NkK3Ni=>
H211 MmjnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFP4Tpp,PSEQvF2= NFrSSphFVVOR MX3JR|UxRTBwN{OzJO69VQ>? NWTSOYFSOTl7OU[yO|I>
HCC70 MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NV73cpBmhjVizszN MUHEUXNQ MmLvTWM2OD1zLkW1JO69VQ>? NGnOPI0yQTl7NkK3Ni=>
SW116 M2C4bmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1HxPZ42KM7:TR?= MUXEUXNQ NWW5NlE4UUN3ME2wMlA3PyEQvF2= MlzqNVk6QTZ{N{K=
H513 NFHJXFFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M13h[Z42KM7:TR?= M2PkZ2ROW09? NX:5VYVjUUN3ME20MlQ1QCEQvF2= Mlf3NVk6QTZ{N{K=
MDA-MB-157 M2PmfWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUH+OUDPxE1? MVLEUXNQ NW\VXJpyUUN3ME2wMlA{PiEQvF2= MXSxPVk6PjJ5Mh?=
H2052 MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXy3RXp7hjVizszN MYTEUXNQ NYGzVJFlUUN3ME2xMlA2KM7:TR?= M2DtW|E6QTl4Mkey
MDA-MB-415 M4jNcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2LuS542KM7:TR?= NIHsN4NFVVOR NHjxcohKSzVyPkWuNFAh|ryP MojlNVk6QTZ{N{K=
DLD-1 M1X5XGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnjMglUh|ryP M{XaO2ROW09? NYHrUllbUUN3ME2wMlkxQSEQvF2= Ml3NNVk6QTZ{N{K=
H2595 M4qwZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXT1TI92hjVizszN NHnyTpZFVVOR NGLtTJhKSzVyPUSuOFc2KM7:TR?= MUexPVk6PjJ5Mh?=
MDA-MB-435S MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFPENox,PSEQvF2= MXnEUXNQ MVrJR|UxRTFwOE[5JO69VQ>? NFuzbGIyQTl7NkK3Ni=>
HCT15 NIrNRYVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MV3+OUDPxE1? MV7EUXNQ NEW5WXdKSzVyPkGuNFAh|ryP MX2xPVk6PjJ5Mh?=
SK-Hep1 MkX5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlWyglUh|ryP MVrEUXNQ MkHHTWM2OD1yLkG0OkDPxE1? M{H4XVE6QTl4Mkey
MDA-MB-436 NEjSZnpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX3+OUDPxE1? Mn7WSG1UVw>? M{\zR2lEPTB;NT61NFIh|ryP Mn25NVk6QTZ{N{K=
KM12C NFKzZZRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVn+OUDPxE1? NFvORpNFVVOR M1\neWlEPTB;MD6wOVQh|ryP MlziNVk6QTZ{N{K=
HEPG2 MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MV7+OUDPxE1? Mo\ZSG1UVw>? MYDJR|UxRTBwMEK1JO69VQ>? NVjuTYNoOTl7OU[yO|I>
MDA-MB-453 M2qyWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NX[yTnc3hjVizszN NWnoRVhxTE2VTx?= NV;nTIQzUUN3ME2xMlg3QSEQvF2= NVmyOHpZOTl7OU[yO|I>
KM12SM MlPrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWKwZW1bhjVizszN NUXDbJpOTE2VTx?= MlS5TWM2OD1yLkC1PUDPxE1? M1TMd|E6QTl4Mkey
1483 NGPsbHFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYX+OUDPxE1? NUT6eVh7TE2VTx?= M4DmSWlEPTB;Mj6xPUDPxE1? NY\PdnNnOTl7OU[yO|I>
Hs578t NX35cnhvT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3\HfJ42KM7:TR?= MoO2SG1UVw>? NFjUPWtKSzVyPUGuNlg4KM7:TR?= M4K0SVE6QTl4Mkey
LS180 NX\ucFlvT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUT0bWwyhjVizszN MV;EUXNQ MYjJR|UxRTBwNkm2JO69VQ>? NInje2gyQTl7NkK3Ni=>
FaDu MoL3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NH7Qc5p,PSEQvF2= MX\EUXNQ MVfJR|UxRTFwMkeg{txO Mlj0NVk6QTZ{N{K=
ZR-75-1 NEjCb|hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3TVS542KM7:TR?= M3HTWGROW09? NETBRlJKSzVyPUKuNFg1KM7:TR?= NVfsd25UOTl7OU[yO|I>
LS513 MVzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHrQOnV,PSEQvF2= NHLaNnRFVVOR MmXwTWM2OD1yLkGzOUDPxE1? MWWxPVk6PjJ5Mh?=
Detroit.562 NEnZR3JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUT+OUDPxE1? MX;EUXNQ M3jvZmlEPTB;MT6xOEDPxE1? MlyxNVk6QTZ{N{K=
ZR-75-30 M4n0OWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFvSOHl,PSEQvF2= M4jLTmROW09? MnHWTWM2OD53LkCwJO69VQ>? MUexPVk6PjJ5Mh?=
RKO-PM MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NX[5OFJ[hjVizszN M3rT[WROW09? NV\XPGtQUUN3ME2wMlI{OiEQvF2= NUfFbppCOTl7OU[yO|I>
Cal.27 MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mln3glUh|ryP NYDoTIFQTE2VTx?= NVr1Row{UUN3ME2yJO69VQ>? M1HJbVE6QTl4Mkey
KPL4 NIflOmJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWDZ[phOhjVizszN Mnv3SG1UVw>? NFvkeGhKSzVyPUGuNlUzKM7:TR?= NWD4RllkOTl7OU[yO|I>
PKO-RM13 MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MkPVglUh|ryP MV;EUXNQ MYDJR|UxRTBwNEK1JO69VQ>? NYexV4c{OTl7OU[yO|I>
HS.53.T NV3rd4FpT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXf+OUDPxE1? M2DPNGROW09? MlLGTWM2OD1yLke5JO69VQ>? NVPyZpBFOTl7OU[yO|I>
EMT6 NVj2SFAzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mnr2glUh|ryP NH;ZZ4tFVVOR Mlz5TWM2OD1yLkiwOkDPxE1? NIXUUoIyQTl7NkK3Ni=>
SNU-C1 NGfpS2ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUfqcJJPhjVizszN MnP6SG1UVw>? NWrCRWhXUUN3ME2wMlAxPyEQvF2= M1zKdFE6QTl4Mkey
SQCCY1 NYTy[VRHT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFrNNZJ,PSEQvF2= NGTSRm1FVVOR NYG1TFkzUUN3ME2wMlc6KM7:TR?= MkjZNVk6QTZ{N{K=
SW480 MkGzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NF3me2h,PSEQvF2= M4fpTWROW09? M17qc2lEPTB;MD6wN|ch|ryP MVixPVk6PjJ5Mh?=
SCC9 NWHBe2hXT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXvCTpFjhjVizszN M4jTeWROW09? MXvJR|UxRTBwN{Wg{txO MXOxPVk6PjJ5Mh?=
SK-LMS-1 NU\LVHJiT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4HPS542KM7:TR?= MWTEUXNQ NHnMVmNKSzVyPUCuOlg4KM7:TR?= MVixPVk6PjJ5Mh?=
SCC25 NEn4c2xIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M37DNJ42KM7:TR?= MmfXSG1UVw>? NYnuVGpkUUN3ME2wMlY5KM7:TR?= NV35RpZqOTl7OU[yO|I>
U87 NFj6dWJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2fvc542KM7:TR?= MkOySG1UVw>? NEG5TZJKSzVyPUCuPVUh|ryP MWOxPVk6PjJ5Mh?=
SCC15 NX7BWYx{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUK0PHJEhjVizszN NFXRNY1FVVOR NXz3UVhpUUN3ME2wMlY4KM7:TR?= NVjUSnBzOTl7OU[yO|I>
T98G M4rzXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MX\+OUDPxE1? MnX0SG1UVw>? MUfJR|UxRTFwMkG4JO69VQ>? MVqxPVk6PjJ5Mh?=
SCC4 M3SyXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoC5glUh|ryP NHHKU3lFVVOR NYO1TYozUUN3ME2wMlY{KM7:TR?= MlSyNVk6QTZ{N{K=
U118 MmrVS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIjKU4x,PSEQvF2= MYXEUXNQ Mmn3TWM2OD1zLk[xPEDPxE1? NH7aXHYyQTl7NkK3Ni=>
TU167 NYHzNpAyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVX+OUDPxE1? NHPNUJZFVVOR NIDxWnVKSzVyPUSuOVIh|ryP NV3rRnh[OTl7OU[yO|I>
NCI-H727 MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUP+NVDjiIsQvF2= NULXd4VuTE2VTx?= MkfDTWM2OD12Mkigcm0> M1i4SFIxOzh3N{S3
NCI-H720 NID5dGFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHjBPGJ,OTEkgJtOwG0> M2m1OWROW09? Mly3TWM2OD1{Lkig{txO M{Tw[VIxOzh3N{S3
NCI-H835 MnvtS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M{nDNZ4yOOLCit88US=> NVToSWhHTE2VTx?= Mom5TWM2OD1zIN88US=> Mn75NlA{QDV5NEe=
NCI-H727 NUOxSWxPU2mwYYPlJIF{e2G7 MnjrglEx6oDMzszN M3TNVGROW09? MXnpcohq[mm2czDjc45{fGm2dYTpeoUhUUeIMWKgZZV1d3Cqb4PwbI9zgWyjdHnvci=> MV2yNFM5PTd2Nx?=
RD M2fKNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NEi5O5d,OTEkgJtOwG0> NFjBSHBKSzVyPUGuNVIhyrWP NWTUPVhqOjF{OUi3OFU>
Rh41 NGPq[2lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWr+NVDjiIsQvF2= MUHJR|UxRTBwMEegxtVO MYqyNVI6QDd2NR?=
Rh18 M4W0NWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2\QTp4yOOLCit88US=> NW[1PXJKUUN3ME20Mlk3KML3TR?= NFvUWXUzOTJ7OEe0OS=>
Rh30 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4GwXp4yOOLCit88US=> NEnGOYRKSzVyPUCuNVkhyrWP M2rKS|IyOjl6N{S1
BT-12 MmDCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVL+NVDjiIsQvF2= NVvSfZRRUUN3ME2wMlc5KML3TR?= NYDqclVjOjF{OUi3OFU>
CHLA-266 M1mwb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3Xa[J4yOOLCit88US=> M{ThWGlEPTB;MD64PUDDvU1? NV;tRndIOjF{OUi3OFU>
TC-71 MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{LZXp4yOOLCit88US=> NHzC[|dKSzVyPUCuNVEhyrWP MVOyNVI6QDd2NR?=
CHLA-9 MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2q3fZ4yOOLCit88US=> M{j2[2lEPTB;MD6xNkDDvU1? M4PwVlIyOjl6N{S1
CHLA-10 MlS5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2rreZ4yOOLCit88US=> MnK3TWM2OD1yLk[yJOK2VQ>? NYnTbWoxOjF{OUi3OFU>
CHLA-258 NXvIUph7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHTDRZd,OTEkgJtOwG0> MljZTWM2OD1yLkK3JOK2VQ>? NGDpd4wzOTJ7OEe0OS=>
GBM2 NVjvR5FlT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVLWWJlnhjFy4pEK{txO MULJR|UxRTFwNEegxtVO M4ficFIyOjl6N{S1
NB-1643 NX\MdXhsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{H1ZZ4yOOLCit88US=> MXTJR|UxRTBwMUKgxtVO NHXyc3MzOTJ7OEe0OS=>
NB-EBc1 MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHHoWFh,OTEkgJtOwG0> MlnlTWM2OD1yLkO1JOK2VQ>? NGX5fJozOTJ7OEe0OS=>
CHLA-90 MkD3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGDpUpV,OTEkgJtOwG0> NVLDSHN2UUN3ME2wMlc4KML3TR?= Ml72NlEzQTh5NEW=
CHLA-136 NUPVbZVOT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGLxd4Z,OTEkgJtOwG0> M{nI[WlEPTB;MD61NkDDvU1? M4eyeVIyOjl6N{S1
NALM-6 NXjFTWk5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYH+NVDjiIsQvF2= NXPXbmNTUUN3ME2wMlQ6KML3TR?= MVyyNVI6QDd2NR?=
COG-LL-317 MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2DKT54yOOLCit88US=> NHuyOodKSzVyPUGuN|ghyrWP MXmyNVI6QDd2NR?=
RS4;11 NFn6[HVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXXUfnpmhjFy4pEK{txO MlfqTWM2OD1yLkO4JOK2VQ>? MkC5NlEzQTh5NEW=
MOLT-4 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MV7+NVDjiIsQvF2= M4nRWmlEPTB;MD61N{DDvU1? MWeyNVI6QDd2NR?=
CCRF-CEM M3;ESWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M372NJ4yOOLCit88US=> M{\HeGlEPTB;MT6xN{DDvU1? NIfsTIszOTJ7OEe0OS=>
Kasumi-1 NFzOXW5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGewZ3Z,OTEkgJtOwG0> MoDKTWM2OD1zLkKgxtVO NX7RV4l1OjF{OUi3OFU>
Karpas-299 NWDYRXByT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4jaNp4yOOLCit88US=> NWfmUXRmUUN3ME2xMlY1KML3TR?= M4iwR|IyOjl6N{S1
Ramos-RA1 Mli1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFjhfnh,OTEkgJtOwG0> MWfJR|UxRTFwM{GgxtVO MWOyNVI6QDd2NR?=
Rh30  MlqzSpVv[3Srb36gZZN{[Xl? NWL5U294cW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u NFTTUlIzPTl{NUO3PC=>
Rh41 MmHrSpVv[3Srb36gZZN{[Xl? NHTxdnlqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:|cHjvdplt[XSrb36= NW\YdodROjV7MkWzO|g>
RD NGC2dFlHfW6ldHnvckBie3OjeR?= MWPpcoR2[2W|IHHuJIlv[3KnYYPlJI9nKFOISzDwbI9{eGixconsZZRqd25? NFy5NYozPTl{NUO3PC=>
A549 M3HFWmtqdmG|ZTDhd5NigQ>? MXWwMlXjiIsQvF2= MVzEUXNQ M4rEdYlvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v M12we|I3QTJ6NUe4
NCI-H358 NXnHflczU2mwYYPlJIF{e2G7 NWrJeWVlOC534pEK{txO MYTEUXNQ M1HBXolvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v NVi2cZNJOjZ7Mki1O|g>
A549 Mn3KSpVv[3Srb36gZZN{[Xl? MlLUNE426oDMzszN MmDCSG1UVw>? MmjPZ4F2e2W|IHGgZ49v[3W{cnXueEBl\WO{ZXHz[UBqdiCyaH;zdIhwenmuYYTl[EBCU1RiYX7kJGVTUw>? NG\3SGgzPjl{OEW3PC=>
NCI-H358 NHvzc2xHfW6ldHnvckBie3OjeR?= MXmwMlXjiIsQvF2= NVWyXHl6TE2VTx?= NH;sNnZk[XW|ZYOgZUBkd26ldYLy[Y51KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGNVDDhcoQhTVKN Mlq4NlY6Ojh3N{i=
A549 MofPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWH+NVDjiIsQvF2= NXzkeZg{TE2VTx?= MWDJR|UxRTBwN{[g{txO M1W0RVI3QTJ6NUe4
NCI-H358 NHH4dolIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NInTfJh,OTEkgJtOwG0> Mn\qSG1UVw>? NXrvVItYUUN3ME2xMlA6KM7:TR?= NEfOXGEzPjl{OEW3PC=>
A549 NH\oVIxCeG:ydH;zbZMh[XO|YYm= M2HxRVAvPeLCit88US=> NV7lRpBQTE2VTx?= NWjJfYhjcW6mdXPld{BCeG:ydH;zbZM> NXfnWGpXOjZ7Mki1O|g>
NCI-H358 MVrBdI9xfG:|aYOgZZN{[Xl? NFzIR2wxNjYkgJtOwG0> M2LDWGROW09? NYfabHh6cW6mdXPld{BCeG:ydH;zbZM> M2nmclI3QTJ6NUe4
A549 MoTnSpVv[3Srb36gZZN{[Xl? NEX3VJQxNjYkgJtOwG0> NXXPVmR3TE2VTx?= NGj5NWZz\WS3Y3XzJJdwfW6mIHPsc5N2emV? MVqyOlkzQDV5OB?=
NCI-H358 MW\GeY5kfGmxbjDhd5NigQ>? Ml;ZNE426oDMzszN NVvIbFRqTE2VTx?= NHLWTG9z\WS3Y3XzJJdwfW6mIHPsc5N2emV? NVjB[JkzOjZ7Mki1O|g>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 26136493     


(C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.

26136493
Growth inhibition assay
Cell viability; 

PubMed: 30754629     


Response of SK-CO-1 to various drugs and drug combinations.

30754629
体内研究 BMS-754807(12.5mg/kg,口服)作用于携带 IGF-1R-Sal肿瘤的裸鼠,抑制肿瘤和血清中IGF-1R磷酸化。BMS-754807作用于一组选定的上皮(IGF-1R-Sal, GEO, 和Colo205),造血(JJN3)和间质(RD1和Rh41)移植瘤模型,抑制肿瘤生长,肿瘤生长抑制率从53%至115%不等。[1] BMS-754807 (6.25 mg/kg) 作用于转基因的IGF-Sal肿瘤小鼠模型,完全抑制肿瘤生长,且抑制pIGF-1R 和 pAKT。BMS-754807与小鼠血浆和人类血浆的蛋白结合率分别为98.5% 和95.9%。BMS-754807 (25 mg/kg)作用于携带KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), 和 OS-1移植瘤的小鼠模型,显著抑制肿瘤。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

激酶抑制实验:

在体外激酶实验中使用重组人类 IGF-1受体酶测定BMS-754807,在生化实验中使用合成肽KKSRGDYMTMQIG 作为磷酸受体底物测定BMS-754807。在Ubottom 384孔板中使用 30 μL实验缓冲液 (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT)来进行酶活测定。通过结合ATP,1.5 μM 荧光标记肽底物, 酶和BMS-754807而开始反应,反应持续60分钟。加入EDTA终止反应。通过电泳分离荧光底物和磷酸化产物,然后在Caliper LabChip 3000上分析反应混合物。通过对剂量反应曲线进行非线性回归分析而获得IC50值。
细胞实验:[1]
- 合并
  • Cell lines: IGF-1R-Sal, RH41 和 Geo 细胞系
  • Concentrations: 365 nM
  • Incubation Time: 72 小时
  • Method: 细胞按最佳密度培养在RPMI + GLUTAMAX培养基中,培养基中含有有10% 热灭活的胎牛血清(FBS),10mMHepes,青霉素和链霉素。BMS-754807处理细胞72小时后,通过测定3H-胸甘渗透到DNA中的程度而测评细胞增殖。结果表示为IC50。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带IGF-1R-Sal, GEO, Colo205, JJN3, RD1 或 Rh41 肿瘤的裸鼠
  • Dosages: 150 mg/kg
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 92 mg/mL (199.35 mM)
Ethanol 92 mg/mL (199.35 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 461.49
化学式

C23H24FN9O

CAS号 1001350-96-4
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品

Tags: 购买BMS-754807 | BMS-754807供应商 | 采购BMS-754807 | BMS-754807价格 | BMS-754807生产 | 订购BMS-754807 | BMS-754807代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID